Filing Flows › Spero Therapeutics (SPRO) › Q4 2024
Spero Therapeutics (SPRO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
Spero Therapeutics (SPRO) reported revenue of $15.0M for the fourth quarter 2024 (Q4 2024), -80% from a year earlier and +12% from the quarter before. Operating margin was -144.4%, net loss $20.9M (138.8% of revenue).
Spero Therapeutics, Q4 2024: revenue $15.0M (-80% year over year), operating margin -144.4%, net loss $20.9M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.0M | +12% | -80% |
| Operating profit | −$21.7M | — | — |
| Net earnings | −$20.9M | — | — |
| Operating cash flow | −$23.4M | — | — |
What changed
Revenue was $15.0M in Q4 2024, down 80% year over year and up 12% from the previous quarter.
Operating costs exceeded revenue by $21.7M, an operating margin of -144.4%. Total costs grew 60% against a revenue fall of 80%. The fastest-growing cost line was Research & development (+74%). The quarter ended with a net loss of $20.9M, wider than the previous quarter's $17.1M loss.
Operating cash flow was −$23.4M. Non-cash charges added back $1.5M of share-based compensation. Working capital and other items used $4.0M.
Questions
What was Spero Therapeutics' revenue in the fourth quarter 2024?
Spero Therapeutics (SPRO) reported revenue of $15.0M for the fourth quarter 2024 (Q4 2024), -80% from a year earlier and +12% from the quarter before.
Was Spero Therapeutics profitable in the fourth quarter 2024?
Operating loss was $21.7M (-144.4% of revenue) and net loss $20.9M.
Source: Spero Therapeutics 10-K on SEC EDGAR.